The incorrect figure legend was printed for Figure 2. The first sentence of the legend should read as follows: “Choosing glucose-lowering medication in those with indicators of high-risk or established atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure (HF).” The online version of the article (https://doi.org/10.2337/dci19-0066) has been updated to correct this error.
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D'Alessio, D. A., Davies, M. J., Erratum: 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). (Diabetes Care, (2020) 43, (487-493), 10.2337/dci19-0066), <<DIABETES CARE>>, 2019; 43 (7): 1670-1670. [doi:10.2337/dc20-er07] [http://hdl.handle.net/10807/203298]
Erratum: 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). (Diabetes Care, (2020) 43, (487-493), 10.2337/dci19-0066)
Mingrone, Geltrude;
2020
Abstract
The incorrect figure legend was printed for Figure 2. The first sentence of the legend should read as follows: “Choosing glucose-lowering medication in those with indicators of high-risk or established atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure (HF).” The online version of the article (https://doi.org/10.2337/dci19-0066) has been updated to correct this error.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
